https://www.lookmedchina.com/news-everything-you-should-know-about-trocar-needles.html

The safety and effectiveness of medical devices are the cornerstone of clinical application. As active or passive invasive devices, disposable double-ended cannula needles are subject to strict requirements during both pre-market approval and post-market supervision. This article will explore the compliance path by covering aspects such as the regulatory framework at home and abroad, key points of risk analysis, and adverse event monitoring.

I. Requirements for Registration with the China National Medical Products Administration

In China, disposable double-ended catheter needles are usually classified as Class II or Class III medical devices (depending on whether they come into contact with the central circulation system or whether they have a drug coating). The registration process involves:

• Classification Definition: If the product only has the mechanical puncture function and no energy supply, it is classified as Class II; if it has functions such as electrocoagulation, video recording, or drug sustained-release, it is upgraded to Class III.
• Type Inspection: It needs to be completed at a nationally recognized testing center, covering items such as size, puncture force, sealing performance, compatibility performance, and biocompatibility (GB/T 16886 series).
• Clinical Trials: Class II products are usually exempt from clinical trials, but a comparison literature of the same product type needs to be provided; Class III products need to undergo a prospective randomized controlled trial, with the primary endpoint being puncture success rate and complication occurrence rate.

Quality Management System: The manufacturing enterprise needs to obtain ISO 13485 certification and undergo on-site inspections by NMPA.

II. FDA 510(k) and CE MDR

• The US FDA: Most disposable double-tipped cannula needles can be marketed through the 510(k) process, and it is necessary to prove substantial equivalence to legally marketed products (Predicate Device). Key comparison indicators include: needle tip geometric dimensions, puncture force curve, and seal valve lifespan. In recent years, the FDA has strengthened safety reviews of coating materials, requiring the provision of dissolution and degradation product data.
• The EU CE: According to MDR 2017/745, a notified body (NB) must be designated for review. Special emphasis is placed on clinical evaluation (MEDDEV 2.7/1 Rev.4) and post-market clinical follow-up (PMCF). New risks brought by the double-head structure (such as failure of switching mechanisms, fragment detachment) need to be analyzed in detail in the risk management report.

III. Key Points of Risk Management

According to ISO 14971, the risk analysis for disposable double-ended catheter needles should focus on the following aspects:

R1 Stuck double-head switching mechanism Unable to complete operation, forced needle removal Design redundant mechanism, add manual unlocking function; 100% switching force test at factory R2 Premature failure of sealing valve Loss of pneumoperitoneum pressure, interruption of surgery Select high fatigue life materials; simulate 500 times of instrument exchange for accelerated aging test R3 Needle tip fracture remaining in body Tissue damage, requiring secondary surgery Adopt high-strength stainless steel; design weak points at the base of the needle tip to ensure fracture occurs outside the body R4 Coating detachment particles Local inflammation or embolism Coating adhesion test (grid method); limit the maximum particle size to ≤ 10 μm

IV. Post-listing Supervision and Adverse Events

The adverse event reports of the disposable double-tipped cannula needles mainly include: failed puncture, air leakage during pneumoperitoneum, postoperative infection at the puncture site, and instrument fracture, etc. According to the FDA MAUDE database, a total of 287 related reports were received in 2023, of which approximately 12% involved issues with the double-tipped structure (such as malfunction in switching). The manufacturer needs to establish a rapid response mechanism, conduct root cause analysis for similar problems, and, if necessary, initiate a recall.

V. Future Regulatory Trends

• UDI Unique Identifier: Major markets worldwide have implemented UDI as a mandatory measure to facilitate traceability and recall. Due to the complex structure of double-ended cannula needles, it is recommended to simultaneously mark the product batch and the batch of key components on the packaging.
• Real-world evidence: Regulatory authorities are increasingly emphasizing real-world data (RWD) and encouraging companies to collect postoperative follow-up data for supporting indication expansion or update of the product manual.
• Sustainable development regulations: The EU is discussing ecological design requirements for disposable medical devices. In the future, it may restrict the use of non-recyclable plastics, forcing companies to develop environmentally friendly alternative solutions.

Summary

The journey towards compliance for disposable double-ended cannula needles is fraught with challenges, but it is also a necessary step in building product credibility. Companies should incorporate risk control concepts from the very beginning of the design process and ensure their implementation throughout the entire lifecycle of research and development, production, and post-market launch. Only in this way can they win the trust of doctors and patients and remain invincible in the fierce market competition.